0001493152-24-008941.txt : 20240306 0001493152-24-008941.hdr.sgml : 20240306 20240306070746 ACCESSION NUMBER: 0001493152-24-008941 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240306 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InspireMD, Inc. CENTRAL INDEX KEY: 0001433607 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262123838 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35731 FILM NUMBER: 24724350 BUSINESS ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 BUSINESS PHONE: (888) 776-6804 MAIL ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 FORMER COMPANY: FORMER CONFORMED NAME: Saguaro Resources, Inc. DATE OF NAME CHANGE: 20080428 8-K 1 form8-k.htm
false 0001433607 0001433607 2024-03-06 2024-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): March 6, 2024

 

InspireMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35731   26-2123838
(Commission
File Number)		   (IRS Employer
Identification No.)

 

4 Menorat Hamaor St.
Tel Aviv, Israel		   6744832
(Address of Principal Executive Offices)   (Zip Code)

 

(888) 776-6804

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 6, 2024, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the fourth quarter and year ended December 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
99.1   Press release, dated March 6, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSPIREMD, INC.
   
Date: March 6, 2024 By: /s/ Craig Shore
  Name: Craig Shore
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

 

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 -

 

- Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime -

 

- Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TCAR), as well as Dr. William Gray, as advisor to the company -

 

—

 

Management to host investor conference call today, March 6, at 8:30am ET

 

—

 

Tel Aviv, Israel and Miami, FL — March 6, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

 

Fourth Quarter 2023 and Recent Developments:

 

●Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.

 

●Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.

 

●Announced presentation of positive 30-day results from the C-GUARDIANS U.S. clinical trial of CGuard EPS at the Vascular InterVentional Advances Annual Meeting (VIVA23) and the VEITH Symposium. The results demonstrated that patients with carotid artery stenosis and at high risk for carotid endarterectomy (CEA) had an overall major adverse event rate (death, stroke or myocardial infarction, or DSMI) of 0.95% from procedure through 30 day follow up when treated with carotid artery stenting (CAS) using the CGuard EPS.

 

●Announced re-certification of the Company’s CE Mark under the European Union’s new Medical Device Regulation (MDR) regulatory framework.

 

●Named Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ neuroprotection system for use with CGuard Prime in TCAR procedures.

 

●Appointed William Gray, M.D., system chief of the cardiovascular division at Main Line Health in Wynnewood, PA and professor of medicine at Thomas Jefferson University in Philadelphia, PA, as an advisor to the Company.

 

●Announced a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions.

 

●Announced support for the Centers for Medicare and Medicaid Services’ (CMS) final National Coverage Determination expanding coverage for CAS to include both asymptomatic and standard risk patients, significantly expanding the U.S. CAS addressable market.

 

●Announced the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.

 

 

 

 

 

Marvin Slosman, CEO of InspireMD, commented: “We delivered another strong quarter of sales growth in our approved CE Mark territories while at the same time advancing our U.S. clinical trial and product development pipeline. Our total revenue of $1.76 million represents a record quarter and an increase of nearly 72% over the comparable period in 2022. Notably, we sold over 3,100 stents, up more than 74% year-over-year and bringing our real-world experience to more than 48,000 stents sold to date. The receipt of formal recertification of our CE Mark under the EU’s new Medical Device Regulation (MDR) regulatory framework just a few weeks ago allows us to now leverage the new product development pathway and the latest regulatory certification provided under MDR.

 

“Also during the quarter, we were extremely pleased to report 30-day follow-up data from our C-GUARDIANS clinical trial at VIVA23 and the VEITH Symposium, which are among the most important annual gatherings of specialists who treat vascular disease. The data showed that stenting with CGuard in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95% from procedure through 30 days, which compares favorably to both surgery and alternative stenting options and represents best in class results to date of any pivotal trial of carotid intervention. We remain on track to report 12-month follow-up data mid-year, followed by the submission of our Premarket Approval (PMA) application.

 

“Finally, we made progress advancing our new product pipeline by announcing the lead PIs for our upcoming C-GUARDIANS II clinical trial of our SwitchGuard NPS for use with CGuard Prime in TCAR procedures. We also announced an agreement with Jacobs Institute to conduct an early feasibility study of CGuard Prime to treat patients with acute ischemic stroke and tandem lesions.

 

“We believe InspireMD is uniquely positioned with a best-in-class implant and solutions to support both CAS and TCAR procedures, with line-of-sight to significant clinical and regulatory catalysts this year and next,” Mr. Slosman concluded.

 

Financial Results for the Fourth Quarter Ended December 31, 2023

 

For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022. This increase was predominantly driven by the CE Mark recertification which occurred subsequent to the end of the fourth quarter 2022.

 

Gross profit for the fourth quarter of 2023 increased by $307,000, or 155.1%, to $505,000, compared to a gross profit of $198,000 for the fourth quarter of 2022. This increase resulted from higher revenue and a decrease in miscellaneous expenses. Gross margin (gross profits as a percentage of revenue) increased to 28.7% during the three months ended December 31, 2023, from 19.3% during the three months ended December 31, 2022.

 

Total operating expenses for the fourth quarter of 2023 were $6,313,000, an increase of $1,179,000, or 23.0% compared to $5,134,000 for the fourth quarter of 2022. This increase was primarily due to increases in expenses related to the salaries and share-based compensation offset by a reduction in clinical trial expenses as we near completion of the C-GUARDIANS trial.

 

Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022. This increase was primarily due to a $349,000 increase in interest income from investment in marketable securities, money market funds and short-term bank deposits.

 

Net loss for the fourth quarter of 2023 totaled $5,405,000, or $0.16 per basic and diluted share, compared to a net loss of $4,845,000, or $0.60 per basic and diluted share, for the same period in 2022.

 

As of December 31, 2023, cash, cash equivalents, short-term bank deposits and marketable securities were $39.0 million compared to $17.8 million as of December 31, 2022.

 

 

 

 

 

Financial Results for the full year ended Dec 31, 2023

 

For the twelve months ended December 31, 2023, total revenue increased by $1,034,000, or 20.0%, to $6,205,000, from $5,171,000 during the twelve months ended December 31, 2022. This increase was driven by a 21.1% increase in sales of CGuard EPS, to $6,205,000 during the twelve months ended December 31, 2023, from $5,123,000 during the twelve months ended December 31, 2022. This sales increase was mainly due to growth in existing and new markets.

 

Gross profit for the twelve months ended December 31, 2023, increased by $690,000, or 61.8%, to $1,807,000, compared to a gross profit of $1,117,000 for the twelve months ended December 31, 2022. This increase in gross profit resulted from higher revenue and a decrease in write-off and miscellaneous expenses. Gross margin increased to 29.1% during the twelve months ended December 31, 2023, from 21.6% during the twelve months ended December 31, 2022.

 

Total operating expenses for the twelve months ended December 31, 2023 were $22,950,000, an increase of $3,120,000, or 15.7% compared to $19,830,000 for the twelve months ended December 31, 2022. This increase was primarily due to increases in expenses related to salaries and share-based compensation offset by a reduction in clinical and product development expenses.

 

Total financial income for the twelve months ended December 2023, was $1,292,000, an increase of $1,042,000 or 417% compared to $250,000 for the twelve months ended December 31, 2022. This increase was primarily due to a $1,152,000 increase in interest income from investment in marketable securities, money market funds and short-term bank deposits.

 

Net loss for the twelve months ended December 31, 2023 totaled $19,916,000, or $0.82 per basic and diluted share, compared to a net loss of $18,491,000, or $2.35 per basic and diluted share, for the twelve months ended December 31, 2022.

 

Conference Call and Webcast Details

 

Management will host a conference call at 8:30AM ET today, March 6th, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Wednesday, March 6th at 8:30 a.m. ET

 

  Domestic: 1-877-407-4018
  International: 1-201-689-8471
  Conference ID: 13744173
  Webcast: Webcast Link – Click Here

 

About InspireMD, Inc.

 

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.

 

We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

 

 

 

 

 

Forward-looking Statements

 

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Investor Contacts:

 

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

craigs@inspiremd.com

 

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390

chuck@lifesciadvisors.com

 

investor-relations@inspiremd.com

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS (1)

(U.S. dollars in thousands, except per share data)

 

   Three months ended   Twelve months ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
Revenues  $1,761   $1,026   $6,205   $5,171 
Cost of revenues   1,256    828    4,398    4,054 
                     
Gross Profit   505    198    1,807    1,117 
                     
Operating Expenses:                    
Research and development   2,035    2,013    7,981    7,810 
Selling and marketing   1,309    1,087    3,865    3,664 
General and administrative   2,969    2,034    11,104    8,356 
                     
Total operating expenses   6,313    5,134    22,950    19,830 
                     
Loss from operations   (5,808)   (4,936)   (21,143)   (18,713)
                     
Financial expenses (income)   (468)   (119)   (1,292)   (250)
                     
Loss before tax expenses   (5,340)   (4,817)   (19,851)   (18,463)
                     
Tax expenses   65    28    65    28 
                     
Net Loss  $(5,405)  $(4,845)  $(19,916)  $(18,491)
                     
Net loss per share – basic and diluted  $(0.16)  $(0.60)  $(0.82)  $(2.35)
                     
Weighted average number of shares of common stock used in computing net loss per share – basic and diluted   33,937,425    8,034,547    24,268,181    7,871,814 

 

(1) All financial information for the twelve months ended December 31, 2023 is derived from the Company’s 2023 audited financial statements and all financial information for the twelve months ended December 31, 2022 is derived from the Company’s 2022 audited financial statements, included in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2023 filed with the Securities and Exchange Commission. All financial information for the three months ended December 31, 2023 and 2022 is derived from the Company’s unaudited, financial statements.

 

 

 

 

 

CONSOLIDATED BALANCE SHEETS (2)

(U.S. dollars in thousands)

 

   December 31,   December 31, 
   2023   2022 
ASSETS          
Current Assets:          
Cash and cash equivalents  $9,640   $4,632 
Short-term bank deposits   -    13,171 
Marketable securities   29,383    - 
Accounts receivable:          
Trade, net   1,804    1,034 
Other   648    213 
Prepaid expenses   578    655 
Inventory   2,106    1,621 
           
Total current assets   44,159    21,326 
           
Non-current assets:          
Property, plant and equipment, net   1,060    917 
Operating lease right of use assets   1,473    1,554 
Funds in respect of employee rights upon retirement   951    856 
           
Total non-current assets   3,484    3,327 
           
Total assets  $47,643   $24,653 
           
LIABILITIES AND EQUITY          
Current liabilities:          
Accounts payable and accruals:          
Trade  $939   $659 
Other   5,081    4,411 
Total current liabilities   6,020    5,070 
           
Long-term liabilities:          
Operating lease liabilities   1,038    1,195 
Liability for employee rights upon retirement   1,084    995 
Total long-term liabilities   2,122    2,190 
           
Total liabilities   8,142    7,260 
           
Equity:          
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively   2    1 
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022, respectively   *    * 
Additional paid-in capital   261,000    218,977 
Accumulated deficit   (221,501)   (201,585)
           
Total equity   39,501    17,393 
           
Total liabilities and equity  $47,643   $24,653 

 

(2) All December 31, 2023 financial information is derived from the Company’s 2023 audited financial statements and all December 31, 2022 financial information is derived from the Company’s 2022 audited financial statements, as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2023 filed with the Securities and Exchange Commission.

 

 

 

 

 

PLACEHOLDER FOR FINANCIALS

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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nspr-20240306.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 nspr-20240306_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 nspr-20240306_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 06, 2024
Entity File Number 001-35731
Entity Registrant Name InspireMD, Inc.
Entity Central Index Key 0001433607
Entity Tax Identification Number 26-2123838
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Menorat Hamaor St.
Entity Address, City or Town Tel Aviv
Entity Address, Country IL
Entity Address, Postal Zip Code 6744832
City Area Code (888)
Local Phone Number 776-6804
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NSPR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inspiremd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm nspr-20240306.xsd nspr-20240306_lab.xml nspr-20240306_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NSPR", "nsuri": "http://inspiremd.com/20240306", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "nspr-20240306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nspr-20240306_lab.xml" ] }, "presentationLink": { "local": [ "nspr-20240306_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://inspiremd.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-008941-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-008941-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001433607 2024-03-06 2024-03-06 iso4217:USD shares iso4217:USD shares false 0001433607 8-K 2024-03-06 InspireMD, Inc. DE 001-35731 26-2123838 4 Menorat Hamaor St. Tel Aviv IL 6744832 (888) 776-6804 false false false false Common Stock, par value $0.0001 per share NSPR NASDAQ false